CDK4/6 Inhibitors and Endocrine Therapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Real-World Cohort
World Journal of Oncology · 2026-12 · 17 (6) · 844-857
DOI: 10.14740/wjon2846 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Oncology, 2026-12. Verfasst von Daniel Marin-Trigueros und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Marin-Trigueros, D., & Landaverde, D. U. (2026). CDK4/6 Inhibitors and Endocrine Therapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Real-World Cohort. World Journal of Oncology, 17(6), 844-857. https://doi.org/10.14740/wjon2846
Vancouver
Marin-Trigueros D, Landaverde DU. CDK4/6 Inhibitors and Endocrine Therapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Real-World Cohort. World Journal of Oncology. 2026;17(6):844-857. doi:10.14740/wjon2846
BibTeX
@article{MarinTrigueros2026,
author = {Marin-Trigueros, Daniel and Landaverde, Denis U.},
title = {CDK4/6 Inhibitors and Endocrine Therapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Real-World Cohort},
journal = {World Journal of Oncology},
year = {2026},
volume = {17},
number = {6},
pages = {844--857},
doi = {10.14740/wjon2846}
}
EUVIMED